Exceptional prognostic testing for prostate cancer
The Decipher® Prostate Cancer Genomic Classifier is a prognostic test that informs treatment decisions for patients with prostate cancer.
- Prognosis/treatment selection
- Recurrence monitoring
IMPROVING CARE FOR PROSTATE CANCER
Decipher Prostate clarifies treatment planning
Veracyte’s Decipher Prostate Genomic Classifier helps physicians and their patients with prostate cancer determine the best treatment plan. The 22-gene test was developed using RNA whole-transcriptome analysis and machine learning,1 which provides a comprehensive approach to evaluating a tumor’s molecular underpinnings. The test is performed on tissue samples obtained during biopsy or surgical removal of the prostate.
The Decipher Prostate test is used to determine how likely the patient’s cancer is to metastasize within the next five years. Armed with this information, the physician may recommend less intensive treatment or earlier, more intensive treatment.2-16 The Decipher Prostate test is designed to give physicians and their patients clarity and confidence in developing a personalized treatment plan.
WHEN THE TEST IS USED
Assess risk after prostate cancer diagnosis or surgery to remove the prostate
The Decipher Prostate test helps match treatment timing and intensity with the tumor’s aggressiveness for patients with prostate cancer. Patients with low risk Decipher scores may undergo less intense treatment, while those with high risk Decipher scores may benefit from treatment intensification.2-16
Serving patients across the US
The Decipher Prostate Genomic Classifier is available to patients and their physicians in the US. All testing is performed in Veracyte’s centralized labs. The test is covered by Medicare and private insurers that collectively cover over 195,000 patients.
Veracyte is developing the Decipher Prostate test so it can be performed in laboratories in Europe and elsewhere outside of the US. This is intended to help make the test accessible to patients all over the world.
Learn about the Decipher Prostate Cancer test
Erho N, et al. PLoS ONE. 2013.
Vince Jr RA, et al. Prostate Cancer Prostatic Dis. 2021.
Kim HL, et al. Prostate Cancer Prostatic Dis. 2019.
Herlemann A, et al. Prostate Cancer Prostatic Dis. 2020.
Berlin A, et al. Int J Radiat Oncol Biol Phys. 2019.
Spratt DE, et al. J Clin Oncol. 2018. 18.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [June 20, 2023]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN = National Comprehensive Cancer Network® (NCCN®).
Spratt DE, et al. J Clin Oncol. 2022.
Nguyen PL, et al. Prostate Cancer Prostatic Dis. 2017.
Nguyen PL. et al. Int J Radiat Oncol Biol Phys. 2023.
Den RB, et al. J Clin Oncol. 2015. .
Ross AE, et al. Prostate Cancer Prostatic Dis. 2016
Marascio J, et al. Prostate Cancer Prostatic Dis. 2019
Feng FY, et al. JAMA Oncol. 2021.
Spratt DE, et al. Eur Urol. 2018.
Dal Pra A, et al. Ann Oncol. 2022
The Decipher Prostate Genomic Classifier is available in the US as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA.
This website contains information on products that are targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.